Elizabeth Pelkofski, MD
Gynecologic Oncology · Cooperstown, NYNPI 1184885576
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Johnson & Johnson at 28.8% of the total. Reporting peaked in 2024 at $473 and has fallen 62.7% since, to $177 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in NY, where the typical reported total is $904.
Across 27 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$202
- AstraZeneca$86
- Novartis$68
- Eisai Inc.$67
- Daiichi Sankyo Inc.$60
- Takeda Pharmaceuticals U.S.A., Inc.$45
- plus $172 from 7 others
What the payments were for
- Food & beverage$702100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $202 |
| AstraZeneca | 4 | $86 |
| Novartis | 3 | $68 |
| Eisai Inc. | 2 | $67 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Incyte Corporation | 2 | $34 |
| Sanofi | 1 | $30 |
| Adaptive Biotechnologies Corporation | 1 | $28 |
| Puma Biotechnology, Inc. | 1 | $25 |
| Novocure Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBREVANT$141
How this compares
$702 in reported general payments places this provider in the 40th percentile of 154 gynecologic oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 12 | $41 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Cooperstown
- Heidi GodoyAlbany$1.1M
- Bhavana PothuriNew York$366K
- Joyce BarlinAlbany$208K
- Wiley BunnSyracuse$201K
- Ghadir SalameBrooklyn$179K
- Richard MooreRochester$124K
- Mario LeitaoNew York$116K
- Konstantin ZakashanskyNew York$93K
- Evelyn CantilloNew York$79K
- Farr NezhatNew York$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.